Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pharmaust Limited ( (AU:NUZ) ) just unveiled an announcement.
Neurizon Therapeutics Limited has announced a change in the date of its 2025 Annual General Meeting to November 26, 2025, to allow shareholders more time to review recent developments and facilitate constructive engagement. The company has also set October 8, 2025, as the deadline for director nominations, separate from the voting process, with further AGM details to be provided in the upcoming Notice of Meeting.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative diseases. The company is advancing its lead drug candidate, NUZ-001, for the treatment of ALS, the most common form of motor neurone disease, and aims to explore its potential for broader neurodegenerative applications.
YTD Price Performance: -8.82%
Average Trading Volume: 348,173
Technical Sentiment Signal: Hold
Current Market Cap: A$76.31M
See more insights into NUZ stock on TipRanks’ Stock Analysis page.